GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » DeferredTaxAndRevenue

Shire (SHPG) DeferredTaxAndRevenue : $0 Mil (As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Shire's current deferred tax and revenue for the quarter that ended in Sep. 2018 was $0 Mil.

Shire DeferredTaxAndRevenue Historical Data

The historical data trend for Shire's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire DeferredTaxAndRevenue Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shire DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Shire's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085